CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositio...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CONNOR, ERIC F COLOMVAKOS, JIM DIMETRIOS PENNELL, ANDREW M. K KHAN, MOHAMMED ASADULLAH GOTTSCHLING, STEPHEN EDMUND |
| description | Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase is also provided.
Des formes cristallines du composé de formule (I), qui module la conversion de l'AMP en adénosine par la 5'-nucléotidase, ainsi que des compositions contenant le composé et des procédés de préparation des formes cristallines sont décrits dans la description de la présente invention. L'invention concerne également l'utilisation d'une telle forme cristalline de formule (I) et des compositions dans le traitement et/ou la prévention d'un ensemble varié de maladies, troubles et affections, y compris du cancer et de troubles liés à l'immunité, qui sont médiés par la 5'-nucléotidase. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3179320A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3179320A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3179320A13</originalsourceid><addsrcrecordid>eNrjZDBzDooMDnH08fH0c1Vw8w_yDVbwd1NwVHB2MTdW8PTz8HTyDPEPUnD0c1EIDXYNVgjxcA1y9XfjYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GhuaWxkYGjobGRCgBAJccJvU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF</title><source>esp@cenet</source><creator>CONNOR, ERIC F ; COLOMVAKOS, JIM DIMETRIOS ; PENNELL, ANDREW M. K ; KHAN, MOHAMMED ASADULLAH ; GOTTSCHLING, STEPHEN EDMUND</creator><creatorcontrib>CONNOR, ERIC F ; COLOMVAKOS, JIM DIMETRIOS ; PENNELL, ANDREW M. K ; KHAN, MOHAMMED ASADULLAH ; GOTTSCHLING, STEPHEN EDMUND</creatorcontrib><description>Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase is also provided.
Des formes cristallines du composé de formule (I), qui module la conversion de l'AMP en adénosine par la 5'-nucléotidase, ainsi que des compositions contenant le composé et des procédés de préparation des formes cristallines sont décrits dans la description de la présente invention. L'invention concerne également l'utilisation d'une telle forme cristalline de formule (I) et des compositions dans le traitement et/ou la prévention d'un ensemble varié de maladies, troubles et affections, y compris du cancer et de troubles liés à l'immunité, qui sont médiés par la 5'-nucléotidase.</description><language>eng ; fre</language><subject>CHEMISTRY ; DERIVATIVES THEREOF ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SUGARS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211223&DB=EPODOC&CC=CA&NR=3179320A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211223&DB=EPODOC&CC=CA&NR=3179320A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CONNOR, ERIC F</creatorcontrib><creatorcontrib>COLOMVAKOS, JIM DIMETRIOS</creatorcontrib><creatorcontrib>PENNELL, ANDREW M. K</creatorcontrib><creatorcontrib>KHAN, MOHAMMED ASADULLAH</creatorcontrib><creatorcontrib>GOTTSCHLING, STEPHEN EDMUND</creatorcontrib><title>CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF</title><description>Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase is also provided.
Des formes cristallines du composé de formule (I), qui module la conversion de l'AMP en adénosine par la 5'-nucléotidase, ainsi que des compositions contenant le composé et des procédés de préparation des formes cristallines sont décrits dans la description de la présente invention. L'invention concerne également l'utilisation d'une telle forme cristalline de formule (I) et des compositions dans le traitement et/ou la prévention d'un ensemble varié de maladies, troubles et affections, y compris du cancer et de troubles liés à l'immunité, qui sont médiés par la 5'-nucléotidase.</description><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDBzDooMDnH08fH0c1Vw8w_yDVbwd1NwVHB2MTdW8PTz8HTyDPEPUnD0c1EIDXYNVgjxcA1y9XfjYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxzo7GhuaWxkYGjobGRCgBAJccJvU</recordid><startdate>20211223</startdate><enddate>20211223</enddate><creator>CONNOR, ERIC F</creator><creator>COLOMVAKOS, JIM DIMETRIOS</creator><creator>PENNELL, ANDREW M. K</creator><creator>KHAN, MOHAMMED ASADULLAH</creator><creator>GOTTSCHLING, STEPHEN EDMUND</creator><scope>EVB</scope></search><sort><creationdate>20211223</creationdate><title>CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF</title><author>CONNOR, ERIC F ; COLOMVAKOS, JIM DIMETRIOS ; PENNELL, ANDREW M. K ; KHAN, MOHAMMED ASADULLAH ; GOTTSCHLING, STEPHEN EDMUND</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3179320A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>CONNOR, ERIC F</creatorcontrib><creatorcontrib>COLOMVAKOS, JIM DIMETRIOS</creatorcontrib><creatorcontrib>PENNELL, ANDREW M. K</creatorcontrib><creatorcontrib>KHAN, MOHAMMED ASADULLAH</creatorcontrib><creatorcontrib>GOTTSCHLING, STEPHEN EDMUND</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CONNOR, ERIC F</au><au>COLOMVAKOS, JIM DIMETRIOS</au><au>PENNELL, ANDREW M. K</au><au>KHAN, MOHAMMED ASADULLAH</au><au>GOTTSCHLING, STEPHEN EDMUND</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF</title><date>2021-12-23</date><risdate>2021</risdate><abstract>Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5'-nucleotidase is also provided.
Des formes cristallines du composé de formule (I), qui module la conversion de l'AMP en adénosine par la 5'-nucléotidase, ainsi que des compositions contenant le composé et des procédés de préparation des formes cristallines sont décrits dans la description de la présente invention. L'invention concerne également l'utilisation d'une telle forme cristalline de formule (I) et des compositions dans le traitement et/ou la prévention d'un ensemble varié de maladies, troubles et affections, y compris du cancer et de troubles liés à l'immunité, qui sont médiés par la 5'-nucléotidase.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3179320A1 |
| source | esp@cenet |
| subjects | CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS |
| title | CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A06%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CONNOR,%20ERIC%20F&rft.date=2021-12-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3179320A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |